Ekf Diagnostics Share Discussion Threads

[mach100] 30/5/2014 21:52

Looking at the trades it seems to me that this is being held down. There seems buying pressure but any move up is quickly reversed. So I wouldn't be surprised if there is some capitulation and this goes to 23 or even 22p. It is is probably worth a punt at those levels. Definitely vulnerable when the buying fizzles out.

[croasdalelfc] 29/5/2014 19:48

Ps the five most prevalent cancers are: breast,lung, bowel, prostate, and melanoma.A biopsy is relatively cheap for melanoma as it's only skin deep, $100 - $1000 if done under a surgical procedure.For lung and bowel, it's more like $2000 to $5000

[croasdalelfc] 29/5/2014 19:34

The first PointMan news looked at melanoma. This looks at bowel and lung cancer which are much more prevalent.The gene mutations can be detected in patients blood using PointMan - it means the patient can avoid an expensive and painful biopsy.

[totaleclipse] 29/5/2014 08:30

I agree, the share needs direction otherwise it will just keep drifting downwards. Half year results will be very influential so that we punters can see evidence of the strategy and whether it has a positive influence on top and bottom lines.

[mach100] 28/5/2014 22:19

Lots of buys but still a tick down. A share that is still looking for direction. I wonder will we see 22p or will today's drop entice some more buyers in?

[andrewbaker] 23/5/2014 11:26

Well ... it looks like there's a committed buyer out there, more so than a seller; so perhaps I need to review here: in my book, if buyers outnumber sellers, that's a positive for the price; so, as this is on my watch-list as a future growth stock, maybe we're at a buy point now.

[andrewbaker] 23/5/2014 11:11

If there is a seller out there, maybe now's the time to join in as it looks like they're being mopped up as they're put on the board: when the mop is full, the price is going to come back again, lol. Seriously though, anyone looking to sell should get in now or risk losing out.

[totaleclipse] 22/5/2014 16:36

Wow! Exciting stuff

[fridgefraser] 22/5/2014 13:20

"what's all that 'price monitoring extension' stuff all about"

Here's the definition from another board.



At 4.30 p.m., automatic execution finishes and the market moves into the auction period. The initial auction period runs for five minutes, during which time market participants can place both market and limit orders.

: A market order is one without a specific price attached, which will be executed at the best prevailing price. A limit order is one that has a specific market price level attached to it.

: A mathematical algorithm is used at the end of the 5-minute period to calculate a single closing price for the auction, calculated to be the price at which the greatest number of shares can be executed.

: During the auction process an indicative closing price is displayed to allow market participants the opportunity to adjust their orders.

: "Almost all the time, the auction process will be completed by 4.36 p.m.," said the Stock Exchange's Wallis.

: Price monitoring extension period

: However, there are two sets of circumstances under which the process can be extended by one, or if necessary two, 5-minute periods.

: The first exception is a price-monitoring extension. If the closing algorithm calculates a price that is more than 5 percent away from the average price during the last 10 minutes of normal trading (4.20 to 4.30 p.m.), the auction process moves into a price-monitoring extension.

If the demand to buy or sell at the close is sufficient to move the price outside the 5 percent band, then the price monitoring extension period allows time for liquidity providing or opportunistic market participants, such as market makers, to enter orders to balance the market.

[totaleclipse] 22/5/2014 08:38

By the way, what's all that 'price monitoring extension' stuff all about?

[totaleclipse] 22/5/2014 08:19

I agree Mach100. The price is going to drift under pressure until management release some really positive number backed statements- not just vague affirmations of the business model. The investors have been let down and management are paying the price for not managing investor expectations better.

[mach100] 21/5/2014 19:23

Not trying to deramp and I think this HPV test will be good, but I think the share price is still looking a bit weak. There must be a seller in the background. There was a 50000 buy today and the price really hasn't moved. Maybe this is the floor but I can see it drift lower.

[totaleclipse] 21/5/2014 08:36

Presumably the two tests have to go side by side. If you test positive for HPV you don't necessarily have cervical cancer- perhaps increased screening by smear test is then warranted. My wife hates the smear test too but it has saved her life- they detected cancerous cells 30 years ago and successfully treated her.

Eventually this will be superceded by vaccination against cervical cancer- a programme that is already underway. This from NHS website. "All girls aged 12 to 13 (in the UK) are offered HPV (human papilloma virus) vaccination as part of the NHS childhood vaccination programme. The vaccine protects against cervical cancer. It's usually given to girls in year eight at schools in England."

[croasdalelfc] 21/5/2014 08:05

The Roche HPV test is controversial as it tests for cervical cancer and women can have it instead of a smear test which they all hate. It's controversial as many academic groups say it shouldn't replace the smear test and should be used alongside it as a co-test. I.e it shouldn't be used as a first line screening test. The FDA say it does what it says on the tin and professional groups should decide on the clinical pathway for patientsThe smear test is invasive and best done in a doctors office or by qualified nurse. Many women hate it so much they miss appointment and risk undetected cervical cancer. I believe the US doesn't have a well structured screening service like the UK and cervical screening is a bit hit and miss ( probably depends on insurance cover)It is perfect in a women's health setting as part of a general screen.

[totaleclipse] 21/5/2014 07:53

Hi Croas... It's early, forgive me, but I 'm not getting the relevance to EKF.

[croasdalelfc] 20/5/2014 23:49

From the RNSThe Roche cobas(R) HPV Test, which tests for a DNA virus that can cause cervical cancer, is the only HPV test that is FDA approved for ASC-US triage, co-testing, and first-line primary cervical screening.This was FDA approved only 3 weeks ago. Below is worth reading. http://ascpresidentsmessage.wordpress.com/2014/04/30/hpv-primary-screening-considerations-for-asc-members/

[croasdalelfc] 20/5/2014 07:18

Selah has agreements covering molecular tests in Cardiovascualr disease, obesity, organ transplant, oncology, corporate wellness programs, and women's health.These are huge , huge markets. They have invested in a whole bunch of top spec testing equipment which hopefully can do dozens or even hundreds of assays a day - fully automated.

[croasdalelfc] 20/5/2014 07:11

A nice new revenue stream of a couple of million $.To me the Board still expect revenue from Selah to be circa $20m this year.EKF should turnover over £50m this year and £70m next

[mach100] 19/5/2014 18:56

I think this will go lower TE. A lot of stocks are getting whacked. There is a trust issue around management judgement. It got a bit of a filip from the directors' buys but that bounce is in reverse. 22p on its way. That said, it might be interesting at that level.

[totaleclipse] 19/5/2014 17:28

Crikey! Over 1 and a half million shares sold and the price down 1.5 pence- what is going on? Bears out of hibernation?

[totaleclipse] 16/5/2014 17:04

Interesting to note that Walbrook PR reads these postings. Presumably they take such investor feedback to the EKF Directors. How about some update on the likely 6 monthly figures chaps? Let's get these shares moving upwards again

[croasdalelfc] 15/5/2014 22:09

Looks like the work of an Intern, probably been sacked by now, oops!